Other News

HealthTech Arkansas and MedAxiom Collaborate to Launch HeartX, A Cardiovascular Accelerator Program

LITTLE ROCK, Ark., May 17, 2022 /PRNewswire/ — HealthTech Arkansas and MedAxiom have come together to create HeartX, a cardiovascular-focused healthcare accelerator, to facilitate guaranteed hospital pilot projects and clinical trials for accomplished, early-stage companies bringing new cardiovascular innovations to market. Applications for the 2022 HeartX cohort are now open, and companies […]

Stents With Torsional Strength for Superficial Femoral Artery Disease: The Prospective Q3-Registry

Q3 Medical Devices Bi-Directional Stent, QualiMed Innovative Medizinprodukte GmbH, Winsen, Germany Results Published DUBLIN, May 17, 2022 /PRNewswire/ — Journal of Endovascular Therapy, 2022 (Impact factor 3.487 source Sage Journals) with title “Stents with torsional strength for Superficial Femoral artery disease. The prospective Q3-Registry” by Thieme et al: “The Q3 SELF-EXPANDING stent offers a novel patented Bi-Directional design providing for a new way of flexibility and torsional conformability that is highly durable and crush resistant working in unison […]

HFSA Releases Position Paper on The Impact of Healthcare Disparities on Patients with Heart Failure

ROCKVILLE, Md.  , May 17, 2022 /PRNewswire/ —  A new position paper published today by the Heart Failure Society of America (HFSA) outlines disparities in healthcare that affect patients with heart failure, including race and ethnicity, socioeconomic factors, and social determinants of health. The statement also presents actions that can be taken to […]

HUYABIO INTERNATIONAL ANNOUNCES COMPLETION OF HBI-3000 PHASE 1 TRIAL AND FDA APPROVAL TO PROCEED WITH DOSE ESCALATION IN PHASE 2

Phase 1 trial evaluated the pharmacokinetics and safety of HBI-3000 when dosed with thestrong CYP2D6 inhibitor, paroxetine SAN DIEGO, May 17, 2022 /PRNewswire/ — HUYABIO International, the leader in accelerating global development of China’s pharmaceutical innovations, today announced the successful completion of a Phase 1 drug-drug interaction clinical trial of HBI-3000, a novel drug for cardioversion […]

Aerovate Therapeutics Presents Phase 1 Data for AV-101, A Novel Dry Powder Inhaled Formulation of Imatinib Being Developed for the Treatment of Patients with Pulmonary Arterial Hypertension (PAH)

AV-101 is being developed to address cellular hyperproliferation and resistance to apoptosis in the pulmonary vasculature, which are key features of the pathophysiology of PAH PAH is an area of high unmet need, and currently approved therapies are limited by acting primarily through vasodilation These Phase 1 results show that […]

Cytokinetics Provides Regulatory Update Related to New Drug Application for Omecamtiv Mecarbil

FDA Plans to Convene Advisory Committee Meeting SOUTH SAN FRANCISCO, Calif., May 17, 2022 (GLOBE NEWSWIRE) — Cytokinetics, Incorporated (Nasdaq: CYTK) today announced the Company recently participated in a mid-cycle communication meeting with the U.S. Food & Drug Administration (FDA) and was informed that the Agency plans to convene an […]

Vivasure Medical Announces Series D Financing to Advance Portfolio of PerQseal Vessel Closure Devices

Funds will support clinical development and regulatory approval of fully absorbable percutaneous closure devices for large-bore vessels GALWAY, Ireland–(BUSINESS WIRE)–Vivasure Medical® (“Vivasure” or the “Company”), a company pioneering novel fully absorbable technology for percutaneous vessel closure, today announced the closing of the first tranche of €22 million ($23M) as part of […]

egnite, Inc. Expands into Cardiovascular Disease Supported by New Data on the State of Care for Patients with Atrial Fibrillation

Company to focus on improving the quality of care for all cardiovascular patients in the U.S. ALISO VIEJO, Calif.–(BUSINESS WIRE)–On the heels of its landmark valvular heart disease (VHD) prevalence abstract published in Journal of the American College of Cardiology (JACC), egnite, Inc. today announced that it has expanded the company’s focus […]